Sofie Berg

1.1k total citations
21 papers, 154 citations indexed

About

Sofie Berg is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Sofie Berg has authored 21 papers receiving a total of 154 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 16 papers in Epidemiology and 8 papers in Surgery. Recurrent topics in Sofie Berg's work include Inflammatory Bowel Disease (17 papers), Microscopic Colitis (11 papers) and Eosinophilic Esophagitis (7 papers). Sofie Berg is often cited by papers focused on Inflammatory Bowel Disease (17 papers), Microscopic Colitis (11 papers) and Eosinophilic Esophagitis (7 papers). Sofie Berg collaborates with scholars based in United States, Canada and Germany. Sofie Berg's co-authors include Remo Panaccione, Anne Robinson, William J. Sandborn, Jen‐Fue Maa, Geert D’Haens, Joel Petersson, Stefan Schreiber, Édouard Louis, Robert Löfberg and Silvio Danese and has published in prestigious journals such as Gastroenterology, International Journal of Radiation Oncology*Biology*Physics and The American Journal of Gastroenterology.

In The Last Decade

Sofie Berg

20 papers receiving 152 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sofie Berg United States	7	140	112	51	46	14	21	154
Giulia Rizzuto Italy	7	159 1.1×	130 1.2×	37 0.7×	27 0.6×	11 0.8×	13	169
Daniel Storey United Kingdom	4	108 0.8×	90 0.8×	23 0.5×	54 1.2×	11 0.8×	9	125
Luisa de Castro Spain	6	160 1.1×	133 1.2×	54 1.1×	25 0.5×	7 0.5×	9	176
An Outtier Belgium	6	149 1.1×	102 0.9×	54 1.1×	60 1.3×	6 0.4×	22	178
Peter M. Irving United Kingdom	3	162 1.2×	121 1.1×	45 0.9×	51 1.1×	7 0.5×	12	186
Rosalba Orlando Italy	7	148 1.1×	109 1.0×	80 1.6×	22 0.5×	9 0.6×	11	175
Katherine Hanigan Australia	6	111 0.8×	74 0.7×	48 0.9×	29 0.6×	5 0.4×	20	131
Christine Olbjørn Norway	8	133 0.9×	109 1.0×	43 0.8×	36 0.8×	19 1.4×	15	214
Costantino Zampaletta Italy	8	115 0.8×	111 1.0×	67 1.3×	22 0.5×	7 0.5×	15	166
Vishal Patel United States	5	109 0.8×	101 0.9×	31 0.6×	19 0.4×	19 1.4×	11	158

Countries citing papers authored by Sofie Berg

Since Specialization

Citations

This map shows the geographic impact of Sofie Berg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofie Berg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofie Berg more than expected).

Fields of papers citing papers by Sofie Berg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sofie Berg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofie Berg. The network helps show where Sofie Berg may publish in the future.

Co-authorship network of co-authors of Sofie Berg

This figure shows the co-authorship network connecting the top 25 collaborators of Sofie Berg. A scholar is included among the top collaborators of Sofie Berg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sofie Berg. Sofie Berg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peyrin‐Biroulet, Laurent, Remo Panaccione, Édouard Louis, et al.. (2024). Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure. Clinical Gastroenterology and Hepatology. 22(10). 2096–2106. 8 indexed citations

Ferrante, Marc, Peter M. Irving, María T. Abreu, et al.. (2023). Maintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial. Journal of Crohn s and Colitis. 18(3). 416–423. 5 indexed citations

Colombel, Jean‐Frédéric, Peter M. Irving, Florian Rieder, et al.. (2023). 947 EFFICACY AND SAFETY OF UPADACITINIB FOR THE TREATMENT OF FISTULAS AND FISSURES IN PATIENTS WITH CROHN'S DISEASE. Gastroenterology. 164(6). S–206. 1 indexed citations

Peyrin‐Biroulet, Laurent, Gareth Parkes, Jesse Siffledeen, et al.. (2023). Tu1723 ENDOSCOPIC AND CLINICAL OUTCOMES OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE BY NUMBER AND TYPE OF PRIOR BIOLOGICS. Gastroenterology. 164(6). S–1094. 1 indexed citations

Ferrante, Marc, Laurent Peyrin‐Biroulet, Axel Dignaß, et al.. (2023). 120 - CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS. Gastroenterología y Hepatología. 46. S152–S152. 3 indexed citations

Peyrin‐Biroulet, Laurent, Subrata Ghosh, Scott D. Lee, et al.. (2022). Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. Alimentary Pharmacology & Therapeutics. 57(5). 496–508. 15 indexed citations

Ferrante, Marc, Laurent Peyrin‐Biroulet, Axel Dignaß, et al.. (2022). S715 Clinical and Endoscopic Improvements With Risankizumab Induction and Maintenance Dosing versus Placebo Are Observed Irrespective of Number of Prior Failed Biologics. The American Journal of Gastroenterology. 117(10S). e498–e499. 4 indexed citations

D’Haens, Geert, Jean‐Frédéric Colombel, Peter Bossuyt, et al.. (2021). 775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn’s Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study. Gastroenterology. 161(2). e28–e28. 3 indexed citations

Peyrin‐Biroulet, Laurent, Édouard Louis, Subrata Ghosh, et al.. (2021). S737 Effect of Risankizumab on Patient-Reported Outcomes in Patients With Crohn’s Disease With Inadequate Response or Intolerance to Conventional And/or Biologic Treatments: Results From Phase 3 MOTIVATE and ADVANCE Trials. The American Journal of Gastroenterology. 116(1). S338–S338. 1 indexed citations

10.

Panaccione, Remo, Stefan Schreiber, Laurent Peyrin‐Biroulet, et al.. (2021). S754 Risankizumab as Induction Therapy in Patients with Moderately to Severely Active Crohn’s Disease Who Failed 1 vs >1 Prior Biologic Treatment: Results From the MOTIVATE Study. The American Journal of Gastroenterology. 116(1). S348–S348. 1 indexed citations

11.

Reinisch, Walter, Remo Panaccione, Peter Bossuyt, et al.. (2020). Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study. Inflammatory Bowel Diseases. 26(10). 1562–1571. 34 indexed citations

12.

Loftus, Edward V., Walter Reinisch, Remo Panaccione, et al.. (2019). Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry. Inflammatory Bowel Diseases. 25(9). 1522–1531. 16 indexed citations

13.

Louis, Édouard, Walter Reinisch, David A. Schwartz, et al.. (2018). Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn’s Disease: A Pooled Analysis of 11 Clinical Studies. Advances in Therapy. 35(4). 563–576. 17 indexed citations

14.

Panaccione, Remo, William J. Sandborn, Geert D’Haens, et al.. (2018). Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials. Journal of Crohn s and Colitis. 12(8). 930–938. 15 indexed citations

15.

Reinisch, Walter, Remo Panaccione, Peter Bossuyt, et al.. (2018). 325 - Factors Driving Treatment Escalation in Crohn's Disease in the Calm Trial. Gastroenterology. 154(6). S–81. 1 indexed citations

16.

Reinisch, Walter, Remo Panaccione, Peter Bossuyt, et al.. (2018). Su1796 - Biomarker Correlation with Endoscopic Outcomes in Patients with Crohn's Disease: Data from Calm. Gastroenterology. 154(6). S–587. 1 indexed citations

17.

Panaccione, Remo, Paul Rutgeerts, William J. Sandborn, et al.. (2017). Adalimumab Efficacy and Safety by Disease Duration: Analysis of Pooled Studies of Crohn's Disease. Gastroenterology. 152(5). S744–S744. 1 indexed citations

18.

Reinisch, Walter, Remo Panaccione, Geert D’Haens, et al.. (2017). PYRAMID Registry: Long-term Safety and Effectiveness of Adalimumab by Baseline Immunomodulator Use in Patients With Crohnʼs Disease. The American Journal of Gastroenterology. 112. S384–S384. 2 indexed citations

19.

Louis, Édouard, Robert Löfberg, Walter Reinisch, et al.. (2016). Mo1791 Adalimumab Treatment Reduces Extraintestinal Manifestations in Patients With Moderate to Severe Crohn's Disease: A Pooled Analysis. Gastroenterology. 150(4). S777–S777. 2 indexed citations

20.

Marijnen, Corrie A.M., Sofie Berg, Sjoerd G. van Duinen, R.T.W.M. Thomeer, & Evert M. Noordijk. (2003). Radiotherapy is effective in patients with glioblastoma multiforme with a very limited prognosis and in patients above 70 years of age. International Journal of Radiation Oncology*Biology*Physics. 57(2). S328–S328. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact